The glucose-dependent insulinotropic mechanism of GLP-1 RAs fundamentally transformed type 2 diabetes management by virtually eliminating hypoglycemia risk—a limitation that had constrained earlier antidiabetic therapies [58]. This evidence concerns the gene GCG and type 2 diabetes mellitus.